Keyword: Spark Therapeutics
Roche's Spark acquisition didn't come easy: The deal proxy shows the company had to fight through a bidding war to land its target.
The Spark buy will make Roche a leader in gene therapy and could expand a hemophilia franchise that's currently spearheaded by Hemlibra.
Novartis figures biopharma companies both large and small will need to embrace alternative payment models for pricey gene and cell therapies.
The cell and gene therapy fields remain in early stages, but Novartis' CEO sees a big future. He's working to position Novartis ahead of the pack.
After winning European approval for its gene therapy Luxturna, Novartis is working on individual reimbursement plans with member countries.
Emgality will likely chase Amgen and Novartis’ first-in-class Aimovig and Teva's Ajovy in the CGRP migraine field.
This week, Goldman Sachs resurrected a burning question: How can pharma companies profit from curing patients with one-time gene and cell therapies?
Never underestimate the power of positivity, which triumphed in the latest round of voting in FiercePharma’s drug-naming shootout.
Intent to focus on the first -ever gene therapy launch in the U.S., Spark Therapeutics has licensed voretigene neparvovec to Novartis in all other markets.
The J.P. Morgan Healthcare Conference was a great place to suss out the general biopharma mood as 2018 begins.
